Neuraxis (NRXS) Non-Current Assets (2022 - 2025)
Neuraxis (NRXS) posted Non-Current Assets of $670846.0 for Q4 2025, down 14.93% sequentially from $788581.0 in Q3 2025, and up 36.52% YoY from $491389.0 in Q4 2024.
Neuraxis (NRXS) Non-Current Assets (2022 - 2025) Analysis & Trends
Neuraxis has reported Non-Current Assets for 4 years, with the latest figure at $670846.0 in Q4 2025.
- Quarterly Non-Current Assets rose 36.52% year-over-year to $670846.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (up 17.21% YoY) and the FY2025 annual result came in at $670846.0, up 36.52% from the prior year.
- Non-Current Assets slipped to $670846.0 in Q4 2025 per NRXS's latest filing, from $788581.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.2 million in Q2 2023 and troughed at $266888.0 in Q4 2023.
- A 4-year average of $600429.0 and a median of $516602.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 73.41% in 2023, then jumped 90.08% in 2024.
- Over 4 years, Non-Current Assets stood at $1.0 million in 2022, then slumped by 73.41% to $266888.0 in 2023, then soared by 84.12% to $491389.0 in 2024, then soared by 36.52% to $670846.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $670846.0, $788581.0, and $469268.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 670,846.00 |
| Sep 30, 2025 | 788,581.00 |
| Jun 30, 2025 | 469,268.00 |
| Mar 31, 2025 | 488,783.00 |
| Dec 31, 2024 | 491,389.00 |
| Sep 30, 2024 | 511,427.00 |
| Jun 30, 2024 | 521,777.00 |
| Mar 31, 2024 | 537,895.00 |
| Dec 31, 2023 | 266,888.00 |
| Sep 30, 2023 | 269,064.00 |
| Jun 30, 2023 | 1.19 Mn |
| Dec 31, 2022 | 1.00 Mn |